This study compared the renoprotective effects of sodium–glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM). Here, SLC5A2 is linked to diabetes mellitus.